DKD induces podocyte lipid accumulation. Dapagliflozin upregulates ERRα and ACOX1, enhancing fatty acid oxidation, reducing lipid toxicity, and restoring podocyte structure. Here, ACOX1 is linked to diabetic kidney disease.